Claims for Patent: 8,815,884
✉ Email this page to a colleague
Summary for Patent: 8,815,884
| Title: | Prolyl hydroxylase inhibitors |
| Abstract: | The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) |
| Inventor(s): | Fitch Duke M., Shaw Antony N., Wiggall Kenneth |
| Assignee: | GlaxoSmithKline LLC |
| Application Number: | US14026164 |
| Patent Claims: | 3. The pharmaceutical composition of claim 2 , wherein said pharmaceutical composition comprises 5-100 mg of said compound.4. A method of treating anemia associated with renal disease in a human comprising administering to such patient a pharmaceutical composition according to .5. A method of treating anemia associated with renal disease in a human comprising administering to such patient a pharmaceutical composition according to .6. A method of treating anemia associated with renal disease in a human comprising administering to such patient a pharmaceutical composition according to .7. The method of claim 4 , wherein said pharmaceutical composition is administered as a daily dose.8. The method of claim 5 , wherein said pharmaceutical composition is administered as a daily dose.9. The method of claim 6 , wherein said pharmaceutical composition is administered as a daily dose. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
